Eisai Co Ltd Spons A (ESALY) 39.3100 $ESALY Does Arena

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eisai Co Ltd Spons A (ESALY) 39.3100 $ESALY

Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...

Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.

Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...

Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.

Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...

Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...

Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.

Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...

Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in
George Budwell, The Motley Fool - Motley Fool - Fri Feb 14, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...

Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.

Can These Obesity Drug Stocks Bounce Back in 2014?
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 1:34PM CST
Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as...

Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.

Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Are Smoking Cessation Drugs Better Than Nicotine-based Products?
Leo Sun, The Motley Fool - Motley Fool - Mon Jan 27, 12:45PM CST
Follow @leokornsun // full story)

JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc.
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 16, 11:20AM CST
On Monday we kicked off the start of the 2014 JPMorgan Healthcare Conference, which is arguably the most important health care conference of the year, bringing together pharmaceutical, biotechnology, and medical device makers all under one roof. ...

10 Countries With the Longest Life Expectancy
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 10, 12:35PM CST
Having been a health care junkie for the better part of a decade now, I still stop and marvel at how impressively global life expectancy rates have improved over the past couple of decades, especially considering that the World Health Organization...

Pipeline Progress at Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 3:05PM CST
Corcept recently announced plans to extend its development program for glucocorticoid receptor (GR) antagonists, including Korlym, into oncology.

The Good News, Bad News for Belviq: …Now the Good News
Eric Ho, The Motley Fool - Motley Fool - Tue Nov 26, 9:57AM CST
Belviq, Arena Pharmaceuticals ' (NASDAQ: ARNA) lead obesity drug, continues to rack up mediocre sales numbers as sales performance continues to lag expectations. Fans of Belviq and Arena still see the drug as a potential blockbuster but questions...

The Good News, Bad News for Belviq: Bad News First…
Eric Ho, The Motley Fool - Motley Fool - Thu Nov 21, 2:02PM CST
Arena Pharmaceuticals and its lead product, weight loss drug Belviq, have had a difficult run since Belviq's launch in June. On its recent conference call, Arena's marketing partner Eisai reported anemic third-quarter Belviq sales of only $4.8...

Arena adds to gains on new Belviq marketing deal
AP - Mon Nov 11, 11:46AM CST
NEW YORK (AP) — Shares of Arena Pharmaceuticals continued to rise Monday after the company expanded a marketing partnership on its weight-loss drub Belviq.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 181

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 31

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 24

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 207

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 51

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 37

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading

Top 5 Most Recently Viewed Articles

Taiwanese Stocks Experience Modest Gains Amid Sector Resilience

Updated Category News Views 269

Taiwanese Stocks Experience Modest Gains Amid Sector Resilience Recently, the Taiwan stock market closed positively, reflecting the strength of key sectors that have buoyed investor confidence. With notable advancements in the Electronic Products Distribution, Machinery, and Rubber sectors, the overall performance of the market was encouraging. Market Performance Overview...

Continue Reading
On Tap Credit Union Empowers Community Through Service Efforts

Updated Category News Views 134

On Tap Credit Union rolled up its sleeves back in 2024, teaming up with Habitat for Humanity to build homes for families in need. This wasn’t just some PR stunt; the credit union’s employees got hands-on, working shoulder-to-shoulder with future homeowners to craft safe spaces. Community vibes were strong, and you could feel the energy in the air as folks chipped in,...

Continue Reading
HomePlunge Unveils NFLPA Exclusive Discount for Members

Updated Category News Views 147

HomePlunge Offers Exclusive Discount to NFLPA Members HomePlunge, renowned for its innovative cold therapy products, is excited to unveil a special $400 discount for members of the National Football League Players Association (NFLPA). This exclusive offer reflects HomePlunge's commitment to promoting wellness among athletes, particularly those who play professional...

Continue Reading
AT&T Announces Exciting Dividend Updates for Shareholders

Updated Category News Views 231

AT&T's Recent Dividend Declaration In a significant move for investors, AT&T has announced a quarterly dividend of $0.2775 per share on its common shares. This announcement was made by the board of directors, emphasizing the company's commitment to providing value to its shareholders. Details on Dividend Payments These dividends are set to be paid on May 1 to shareholders...

Continue Reading
TSU Foundation's Charity Gala Achieves Remarkable Fundraising Success

Updated Category News Views 309

TSU Foundation's Charity Event Surpasses Fundraising Goals The Texas Southern University (TSU) Foundation has announced a successful fundraising achievement, raising a substantial $1.25 million for student scholarships at its annual Tiger Ball event. The celebration was held at the George R. Brown Convention Center, where over 700 attendees, including university leaders,...

Continue Reading